Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dilaforette AB Announces the Appointment of Christina Herder

Published: Wednesday, January 22, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Appointment of Christina Herder as new CEO.

Dilaforette AB has announced the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry.

“We are delighted that Christina is joining Dilaforette. Her expertise and experience will help us take the company forward to successful outcomes in malaria and sickle cell disease. I look forward to working with her over the next years”, says Robin Wright, Chairman of Dilaforette.

Dilaforette is developing sevuparin, a proprietary polysaccharide-based drug, for treatment of hematological crisis in malaria as well as vaso-occlusive crisis in sickle cell disease.

“I am looking forward to lead Dilaforette and to develop sevuparin into new therapies for patients, with a large unmet medical need”, says Christina Herder.

Christina holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Christina Herder joins Dilaforette from Sobi, where she has been working within Corporate Development as well as previously heading up the Portfolio Management in R&D.

She brings over 20 years of experience from pharmaceutical product development from Pharmacia, Medicarb, Biovitrum and Sobi. She has also been board member of Akinion Pharmaceuticals AB, for five years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilaforette Receives Positive COMP Opinion
Positive opinion on orphan drug designation in the EU for sevuparin in sickle-cell disease.
Thursday, January 22, 2015
Dilaforette Presents Results from Exploratory Phase I/II Clinical Trial in Uncomplicated Malaria
Aim of the trial was to study sevuparin in adult patients with uncomplicated falciparum malaria.
Saturday, May 31, 2014
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!